Hepatitis C virus infection: the new global epidemic

References

• Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C infection. Host, viral and environmental factors. J. Am. Med. Assoc. 284, 450–456 (2000).
   PubMed Web of Science ®Google Scholar
• Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341(8), 556–562 (1999).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Prevalence of hepatitis C virus infection among clients of HIV counseling and testing sites – Connecticut, 1999. Morb. Mortal. Wkly Rep. 50, 577–581 (2001).
   PubMedGoogle Scholar
• Staples CT Jr, Rimland D, Dudas D. Hepatitis C in HIV Atlanta VA (Veterans Affairs Medical Center) cohort study (HAVACS): the effect of coinfection on survival. Clin. Infect. Dis. 29, 150–154 (1999).
   PubMed Web of Science ®Google Scholar
• Austin GE, Jensen B, Leete J et al. Prevalence of hepatitis C virus seropositivity among hospitalized US veterans. Am. J. Med. Sci. 319(6), 353–359 (2000).
   PubMedGoogle Scholar
• Briggs ME, Baker C, Hall R et al. Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. Hepatology 34(6), 1200–1205 (2001).
   PubMedGoogle Scholar
• Schneeberger PM, Keur I, van Loon AM et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. J. Infect. Dis. 182(5), 1291–1299 (2000).
   PubMedGoogle Scholar
• Hayashi J, Yoshimura E, Nabeshima A et al. Seroepidemiology of hepatitis C virus infection in hemodialysis patients and the general population in Fukuoka and Okinawa, Japan. J. Gastroenterol. 29(3), 276–281 (1994).
   PubMedGoogle Scholar
• Lamphear BP, Linnemann CC Jr, Cannon CG, DeRonde MM, Pendy L, Keley LM. Hepatitis C virus infection in healthcare workers: risk of exposure and infection. Infect. Control Hosp. Epidemiol.15, 745–750 (1994).
   PubMedGoogle Scholar
• Rischitelli G, Harris J, McCauley L, Gershon R, Guidotti T. The risk of acquiring hepatitis B or C among public safety workers. Am. J. Prev. Med. 20, 299–306 (2001).
   PubMedGoogle Scholar
• Thorburn D, Dundas D, McCruden EA et al. A study of hepatitis C prevalence in healthcare workers in the west of Scotland. Gut 48(1), 116–120 (2001).
   PubMedGoogle Scholar
• Balogun MA, Ramsay ME, Parry JV et al. The prevalence and genetic diversity of hepatitis C infection in antenatal clinic attenders in two regions of England. Epidemiol. Infect. 125, 705–712 (2000).
   PubMed Web of Science ®Google Scholar
• Conte D, Fraquelli M, Prati D, Colucci A, Minola E. Prevalence and clinical course of chronic hepatitis C virus infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 31, 751–755 (2000).
   PubMed Web of Science ®Google Scholar
• Paternoster DM, Santarossa C, Grella P et al. Viral load in HCV RNA-positive pregnant women. Am. J. Gastroenterol. 96, 2751–2754 (2001).
   PubMedGoogle Scholar
• Aslam MMD. Seroprevalence of the antibody to hepatitis C in select groups in the Punjab region of Pakistan. J. Clin. Gastroenterol. 33(5), 407–411 (2001).
   PubMedGoogle Scholar
• Bari A. Risk factors for hepatitis C virus infection in male adults in Rawalpindi-Islamabad, Pakistan. Trop. Med. Int. Health 6(9), 732–738 (2001).
   PubMedGoogle Scholar
• Darwish MA, Faris R, Darwish N et al. Hepatitis C and cirrhotic liver disease in the Nile Delta of Egypt: a community-based study. Am. J. Trop. Med. Hyg. 64, 147–153 (2001).
   PubMed Web of Science ®Google Scholar
• Nafeh MA, Medhat A, Shehta M et al. Hepatitis C in a community in upper Egypt. 1: cross-sectional survey. Am. J. Trop. Med. Hyg. 63, 236–241 (2000).
   PubMed Web of Science ®Google Scholar
• Darby SC, Ewart DW, Giangrande PL et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 350(9089), 1425–1431 (1997).
   Google Scholar
• Khan AJ, Luby SP, Fikree F et al. Unsafe injections and the transmission of hepatitis B and C in a periurban community in Pakistan. Bull.World Health Organ. 78(8), 956–963 (2000).
   PubMedGoogle Scholar
• Alter MJ, Coleman PJ, Alexander WJ et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. J. Am. Med. Assoc. 262(9), 1201–1205 (1989).
   Google Scholar
• Luby SP, Qamruddin K, Shah AA et al. The relationship between therapeutic injections and high prevalence of hepatitis C infection in Hafizabad, Pakistan. Epidemiol. Infect. 119(3), 349–356 (1997).
   PubMedGoogle Scholar
• Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis.20, 1–16 (2000).
   PubMed Web of Science ®Google Scholar
• Farci P, Purcell RH. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin. Liver Dis.20, 103–126 (2000).
   PubMed Web of Science ®Google Scholar
• Blackard JT, Yang Y, Bordoni P, Sherman KE, Chung RT. Hepatitis C virus (HCV) diversity in HIV–HCV-coinfected subjects initiating highly active antiretroviral therapy. J. Infect. Dis. 189(8), 1472–1481 (2004).
   PubMedGoogle Scholar
• Fattovich G, Ribero ML, Pantalena M et al. Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe. J. Viral Hepat.8, 206–216 (2001).
   PubMed Web of Science ®Google Scholar
• Memon MI, Memon MA. Hepatitis C: an epidemiological review. J. Viral Hepat. 9(2), 84–100 (2002).
   PubMedGoogle Scholar
• Conry-Cantilena C, VanRaden M, Gibble J et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N. Engl. J. Med. 334, 1691–1696 (1996).
   PubMedGoogle Scholar
• Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion42(8), 975–979 (2002).
   PubMedGoogle Scholar
• Orton SL, Stramer SL, Dodd RY, Alter MJ. Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV. Transfusion 44(2), 275–281 (2004).
   PubMedGoogle Scholar
• Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 43(6), 721–729 (2003).
   PubMedGoogle Scholar
• Stramer SL, Glynn SA, Kleinman SH et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N. Engl. J. Med. 351, 760–768 (2004).
   PubMed Web of Science ®Google Scholar
• Chou R, Clark EC, Helfand M. Screening for hepatitis C virus infection: a review of the evidence for the US Preventive Services Task Force. Ann. Intern. Med. 140(6), 465–479 (2004).
   PubMedGoogle Scholar
• Alter MJ, Moyer LA. The importance of preventing hepatitis C virus infection among injection drug users in the United States. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 18(Suppl. 1), S6–S10 (1998).
   PubMedGoogle Scholar
• Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 18(Suppl. 1), S11–S19 (1998).
   PubMedGoogle Scholar
• Thorpe LE, Ouellet LJ, Levy JR, Williams IT, Monterroso ER. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997–1999. J. Infect. Dis. 182(6), 1588–1594 (2000).
   PubMedGoogle Scholar
• Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am. J. Public Health 86(5), 655–661 (1996).
   PubMedGoogle Scholar
• Everhart JE, Di Biseeglie AM, Murray LM et al. Risk for non-A, non-B (Type C) hepatitis through sexual or household contact with chronic carriers. Ann. Intern. Med.112, 544–545 (1990).
   PubMed Web of Science ®Google Scholar
• Gordon SC, Patel AH, Kulesza GW, Barnes RE, Silverman AL. Lack of evidence for the heterosexual transmission of hepatitis C. Am. J. Gastroenterol.87, 1849–1851 (1992).
   PubMed Web of Science ®Google Scholar
• Feldman JG, Minkoff H, Landesman S, Dehovitz J. Heterosexual transmission of hepatitis C, hepatitis B, and HIV-1 in a sample of inner-city women. Sex. Transm. Dis.27, 338–342 (2001).
   Google Scholar
• Bonacini M, Puoti M. Hepatitis C in patients with human immunodeficiency virus infection. Diagnosis, natural history, meta-analysis of sexual and vertical transmission and therapeutic issues. Arch. Intern. Med.160, 3365–3373 (2000).
   PubMed Web of Science ®Google Scholar
• Granovsky MO, Minkoff HL, Tess BH et al. Hepatitis C virus infection in the mothers and infants cohort study. Pediatrics 102, 355–359 (1998).
   PubMed Web of Science ®Google Scholar
• Yeung LTF, King SM, Roberts EA. Mother-to-infant transmission of Hepatitis C virus. Hepatology 34, 223–229 (2001).
   PubMed Web of Science ®Google Scholar
• Izopet J, Pasquier C, Sandres K, Puel J, Rostaing L. Molecular evidence for nosocomial transmission of hepatitis C virus in a French hemodialysis unit. J. Med. Virol. 58(2), 139–144 (1999).
   PubMedGoogle Scholar
• Esteban JI, Gomez J, Martell M et al. Transmission of hepatitis C virus by a cardiac surgeon. N. Engl. J. Med. 334(9), 555–560 (1996).
   PubMed Web of Science ®Google Scholar
• Ross RS, Viazov S, Roggendorf M. Risk of hepatitis C transmission from infected medical staff to patients: model-based calculations for surgical settings. Arch. Intern. Med. 160(15), 2313–2316 (2000).
   PubMedGoogle Scholar
• Kiyosawa K, Sodeyama T, Tanaka E et al. Hepatitis C in hospital employees with needlestick injuries. Ann. Intern. Med.115, 367–369 (1991).
   PubMed Web of Science ®Google Scholar
• Haley RW, Fischer RP. Commercial tattooing as a potentially important source of hepatitis C infection: clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status. Medicine 80, 134–151 (2001).
   PubMedGoogle Scholar
• Yerly S, Quadri R, Negro F et al. Nosocomial outbreak of multiple bloodborne viral infections. J. Infect. Dis.184, 369–372 (2001).
   PubMed Web of Science ®Google Scholar
• Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N. Engl. J. Med. 342, 1266–1271 (2000).
   PubMed Web of Science ®Google Scholar
• Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. Hepatology 27, 1213–1219 (1998).
   PubMed Web of Science ®Google Scholar
• Vrielink H, Zaaijier HL, Reesink HW, van der Poel CL, Cuypers HT, Lelie PN. Sensitivity and specificity of three third-generation anti-hepatitis C virus ELISAs. Vox Sang. 69, 14–17 (1995).
   PubMed Web of Science ®Google Scholar
• Atrah HI, Hutchinson F, Gough D, Ala FA, Ahmed MM. Hepatitis C virus seroconversion rate in established blood donors. J. Med. Virol. 46, 329–333 (1995).
   PubMed Web of Science ®Google Scholar
• Tong MJ, El Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med. 332(22), 1463–1466 (1995).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morb. Mortal. Wkly Rep. 47, 1–39 (1998).
   PubMedGoogle Scholar
• Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peginoux M. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 27, 1717–1722 (1998).
   PubMedGoogle Scholar
• Okazaki T, Yoshihara H, Suzuki K, Yamada Y, Tsujimura T, Kawano K. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between nondrinkers and drinkers. Scand. J. Gastroenterol.29, 1039–1043 (1994).
   PubMed Web of Science ®Google Scholar
• Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132(4), 296–305 (2000).
   PubMedGoogle Scholar
• Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am. J. Gastroenterol. 88, 240–243 (1993).
   PubMed Web of Science ®Google Scholar
• Wiley TE, McCarty M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 28, 805–809 (1998).
   PubMed Web of Science ®Google Scholar
• Mathurin P, Moussalli J, Cadranel JF et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 27, 868–872 (1998).
   PubMedGoogle Scholar
• Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N. Engl. J. Med. 340(16), 1228–1233 (1999).
   PubMed Web of Science ®Google Scholar
• Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin. Infect. Dis. 32, 492–497 (2001).
   PubMed Web of Science ®Google Scholar
• Sulkowski MS. Hepatitis C virus infection in HIV-infected patients. Curr. Infect. Disease Reports 3, 469–476 (2001).
   PubMedGoogle Scholar
• Yeo AE, Ghany M, Conry-Cantilena C et al. Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J. Viral. Hepat. 8(4), 256–263 (2001).
   PubMedGoogle Scholar
• Butt AA, Herrine S. Hepatitis C. In: Antimicrobial Therapy and Vaccines, Third Edition. Yu VL, Weber R, Raoult D (Eds). Apple Trees Productions, NY, USA (2002).
   Google Scholar
• Heathcote EJ, Shiffman ML, Cooksley WG et al. Peginterferon-α2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343(23), 1673–1680 (2000).
   PubMedGoogle Scholar
• Lee SS, Sherman M. Pilot study of interferon-α and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values. J. Viral Hepat. 8, 202–205 (2001).
   PubMedGoogle Scholar
• Puoti C, Magrini A, Stati T et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 26(6), 1393–1398 (1997).
   PubMedGoogle Scholar
• Manns MP, McHutchinson JG, Gordon SC et al. Peginterferon α2b plus ribavirin compared with interferon α2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet358, 958–965 (2001).
   PubMed Web of Science ®Google Scholar
• McHutchinson JR, Gordon SC, Schiff ER et al. Interferon-α2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 359, 1485–1492 (1998).
   Google Scholar
• Lindsay KL, Trepo C, Heintges T et al. A randomized, double-blind trial comparing pegylated interferon α2b to interferon α2b as initial treatment for chronic hepatitis C. Hepatology 34(2), 395–403 (2001).
   PubMedGoogle Scholar
• Hayes P. A randomized, double-blind trial comparing pegylated interferon-α2b to interferon-α2b as initial treatment for chronic hepatitis C. Eur. J. Gastroenterol. Hepatol. 13(9), 1132 (2001).
   Google Scholar
• Poynard T, Marcellin P, Lee SS et al. Randomized trial of interferon-α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon-α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352(9138), 1426–1432 (1998).
   PubMed Web of Science ®Google Scholar
• Davis GL, Esteban-Mur R, Rustgi V et al. Interferon-α2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N. Engl. J. Med. 339(21), 1493–1499 (1998).
   PubMedGoogle Scholar
• Hoofnagle JH, Mullen KD, Jones DB et al. Treatment of chronic non-A, non-B hepatitis with recombinant human α-interferon. A preliminary report. N. Engl. J. Med. 315(25), 1575–1578 (1986).
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon α2a in patients with chronic hepatitis C. N. Engl. J. Med. 343, 1666–1672 (2000).
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon-α2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. 351(5), 438–450 (2004).
   PubMed Web of Science ®Google Scholar
• Chung RT, Andersen J, Volberding P et al. Peginterferon-α2a plus ribavirin versus interferon-α2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med. 351(5), 451–459 (2004).
   PubMed Web of Science ®Google Scholar
• Kostman JR, Rodriguez Torres M, Prokupeko D et al. Results of a multicenter randomized, double-blind, controlled trial of interferon-α2b ribavirin/combination therapy in HCV/HIV coinfected persons. 1st IAS conference on HIV pathogenesis and treatment. Buenos Aires, Argentina, 7–11 July 2001 (Abstract 555).
   Google Scholar
• Landau A, Batisse D, Van Huyen JPD et al. Efficacy and safety of combination therapy with interferon-α2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 14, 839–844 (2000).
   PubMed Web of Science ®Google Scholar
• Nasti G, Di Gennaro G, Tavio M et al. Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon α2b and tribavirin. AIDS 15(14), 1783–1787 (2001).
   PubMedGoogle Scholar
• Perez-Olmeda M, Romero M, Asensi V, Sanchez-Montero F, Ochoa A, Garcia-Samaniego J. Efficacy and safety of combination therapy with interferon plus ribavirin in HIV-infected patients with chronic hepatitis C. 52nd Annual Meeting of the American Association for the Study of Liver Diseases. Dallas, TX, USA, 9–13 November 2002 (Abstract 641).
   Google Scholar
• Moreno L, Quereda C, Moreno A et al. Pegylated interferon α2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 18(1), 67–73 (2004).
   PubMedGoogle Scholar
• Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T. Pegylated interferon-α2b and ribavirin in HIV/hepatitis C virus-coinfected nonresponders and relapsers to IFN-based therapy. AIDS 18(1), 75–79 (2004).
   PubMedGoogle Scholar
• Ho SB, Ngyuen H, Tetrick LL, Opitz GA, Basara ML, Dieperink E. Influence of psychiatric diagnoses on interferon-α treatment for chronic hepatitis C in a veteran population. Am. J. Gastroenterol. 96(1), 157–164 (2001).
   PubMedGoogle Scholar
• Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J. Clin. Gastroenterol. 34(3), 268–271 (2002).
   PubMedGoogle Scholar
• Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 35(1), 182–189 (2002).
   PubMedGoogle Scholar
• Butt AA. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. The AIDS Reader 13(7), 344–348 (2003).
   PubMedGoogle Scholar
• Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon-α2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39(6), 1702–1708 (2004).
   PubMedGoogle Scholar
• Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection – a pilot study. J. Viral Hepat. 8(4), 287–292 (2001).
   PubMedGoogle Scholar
• Tan AC, Brouwer JT, Glue P et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol. Dial. Transplant. 16(1), 193–195 (2001).
   PubMedGoogle Scholar